How Much Does Reclast (Zoledronic Acid) Cost in Wisconsin in 2026?

Wisconsin Retail Pricing: List Price vs. What You Actually Pay

The gap between the manufacturer list price and what Wisconsin patients pay out of pocket is wide. Novartis lists Reclast at roughly $1,500 per infusion, a figure that reflects the wholesale acquisition cost before any rebates, discounts, or insurance adjustments take effect. That number rarely represents what a patient hands over at the pharmacy counter or infusion center.

Across Wisconsin retail pharmacies in 2026, the average cash-pay price sits around $600 per infusion. This reflects generic zoledronic acid availability, which entered the U.S. market after Reclast's patent expiration. Generic competition has driven costs down substantially from the branded price point 1.

Pricing varies by location within the state. Milwaukee and Madison infusion centers may charge differently than rural clinics in northern Wisconsin. Hospital outpatient departments typically bill higher facility fees compared to standalone infusion suites or physician offices. Requesting the drug's billing code (J3489 for zoledronic acid) before your appointment lets you compare facility charges directly.

Because zoledronic acid is administered as a once-yearly infusion, even the $1,500 list price translates to a lower annualized cost than many monthly oral bisphosphonates when accounting for adherence gaps. The HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765) demonstrated that annual zoledronic acid 5 mg IV reduced the risk of vertebral fracture by 70% and hip fracture by 41% over three years 2. That efficacy profile makes cost-per-fracture-prevented a useful metric when comparing treatment options.

Wisconsin Medicaid Coverage for Zoledronic Acid

Wisconsin Medicaid does cover Reclast and generic zoledronic acid, but a prior authorization requirement applies. This means your prescriber must submit clinical documentation before the state program will approve payment.

The PA process typically requires evidence of a confirmed osteoporosis diagnosis (T-score of -2.5 or below at the hip or spine on DXA scan), or documentation of a fragility fracture. Wisconsin Medicaid may also require that the patient has tried or has a contraindication to oral bisphosphonates such as alendronate before approving zoledronic acid. The Endocrine Society's 2019 clinical practice guideline supports IV bisphosphonate use when oral agents are not tolerated or when adherence to weekly/monthly oral regimens is a concern [3].

ForwardHealth, Wisconsin's Medicaid management system, processes these authorizations. Turnaround ranges from 48 hours to two weeks depending on documentation completeness. Your prescriber's office can check authorization status through the ForwardHealth portal. If denied, a peer-to-peer review with a Medicaid medical director is the standard appeal pathway.

Patients enrolled in Wisconsin BadgerCare Plus follow similar PA requirements. Dual-eligible beneficiaries (those with both Medicare and Medicaid) may have the infusion covered under Medicare Part B as a physician-administered drug, with Medicaid picking up remaining cost-sharing.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Wisconsin generally cover zoledronic acid for FDA-approved indications. Most plans classify it as a medical benefit rather than a pharmacy benefit because it requires clinical administration. This distinction matters. Medical benefit claims go through different cost-sharing structures than pharmacy copays.

Under Medicare Part B, zoledronic acid is covered at 80% of the Medicare-approved amount after the annual deductible. The patient owes the remaining 20% coinsurance unless a Medigap policy or employer supplemental plan covers it. For a $600 infusion, that 20% coinsurance equals roughly $120 out of pocket 4.

A 2020 analysis in the Journal of Bone and Mineral Research found that Medicare Part D spending on osteoporosis medications dropped 46% between 2012 and 2018, driven partly by generic bisphosphonate availability and partly by declining prescribing rates after the bisphosphonate "drug holiday" debate 5. Wisconsin followed this national pattern. The concern is that undertreatment of osteoporosis, not overtreatment, is the dominant problem. Dr. Ethel Siris of Columbia University has stated: "We have created a treatment gap where the patients at highest fracture risk are the least likely to receive therapy" 5.

Wisconsin-based insurers including Quartz, Group Health Cooperative of South Central Wisconsin, and Security Health Plan each maintain their own formulary criteria. Calling the number on your insurance card and asking specifically about J-code J3489 will get you the most accurate coverage and cost-sharing details for your specific plan.

Compounded Zoledronic Acid in Wisconsin: Legality and Availability

Compounded zoledronic acid is legally available in Wisconsin through licensed 503A compounding pharmacies. These pharmacies operate under individual patient prescriptions and must comply with both Wisconsin Pharmacy Examining Board regulations and federal guidelines under Section 503A of the Federal Food, Drug, and Cosmetic Act 6.

A 503A pharmacy compounds medications based on a valid patient-specific prescription from a licensed prescriber. The drug is not mass-produced or distributed across state lines (that falls under 503B outsourcing facilities, which follow different FDA oversight rules). Wisconsin permits 503A compounding as long as the pharmacy holds a valid state license and the prescriber documents a clinical need.

Cost is the primary draw. Compounded zoledronic acid can be priced well below both branded Reclast and generic versions available through traditional supply chains. However, patients should verify several things before choosing this route. The compounding pharmacy should be accredited by the Pharmacy Compounding Accreditation Board (PCAB) or hold equivalent quality credentials. The prescriber should confirm the compounded formulation matches the 5 mg/100 mL concentration used in clinical trials. Sterility testing documentation should be available on request, since zoledronic acid is an injectable product and sterility failures carry serious infection risk.

The FDA's compounding quality page provides guidance on evaluating compounding pharmacies. Not every 503A pharmacy in Wisconsin compounds zoledronic acid specifically, so availability requires direct inquiry.

Telehealth Prescribing of Reclast in Wisconsin

Wisconsin allows telehealth prescribing of zoledronic acid. A clinician can evaluate a patient via video visit, review DXA results and lab work, and write the prescription without an in-person encounter. The infusion itself still requires a clinical setting (physician's office, infusion center, or hospital outpatient department) with monitoring capability for the 15-minute IV administration and a post-infusion observation period.

Pre-infusion labs are mandatory. Serum calcium and vitamin D levels must be checked and corrected before administration. The FDA prescribing information for Reclast warns against use in patients with hypocalcemia, and adequate calcium and vitamin D supplementation (typically 1 to 200 mg calcium and 800 to 1 to 000 IU vitamin D daily) should be established before the infusion 1.

Wisconsin's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means the evaluation visit leading to a zoledronic acid prescription should not carry additional out-of-pocket cost compared to an office visit. Medicare also covers telehealth visits for osteoporosis management under current CMS flexibilities.

Telehealth is particularly practical for follow-up monitoring. After the initial infusion, patients need periodic assessment of renal function and bone density. These reviews translate well to virtual visits, reducing travel burden for patients in rural Wisconsin counties where endocrinology or rheumatology specialists may be hours away.

Discount Programs and Savings Strategies

Several pathways can lower zoledronic acid costs for Wisconsin patients who face high out-of-pocket expenses.

Novartis Patient Assistance. Novartis operates a patient assistance program for Reclast that covers eligible uninsured or underinsured patients. Income thresholds apply, typically set at 400% of the federal poverty level or below. Applications go through the Novartis Patient Assistance Foundation.

Generic Manufacturer Savings. Generic zoledronic acid manufacturers (including Mylan, Teva, and Hospira) do not typically offer direct-to-patient copay cards for IV-administered drugs the way oral medication manufacturers do. The savings come instead from the lower acquisition cost that facilities pay for generic product. Ask your infusion site whether they stock generic zoledronic acid or branded Reclast, because the cost difference can be $500 or more per infusion.

GoodRx and Prescription Discount Platforms. These platforms can sometimes provide discounted pricing at retail pharmacies that dispense the drug for buy-and-bill arrangements. Results vary. The drug's status as a medical benefit (rather than pharmacy benefit) for most patients limits the applicability of traditional prescription discount cards.

340B Drug Pricing. Wisconsin patients who receive care at 340B-eligible facilities (federally qualified health centers, certain hospital outpatient departments, Ryan White clinics) may access zoledronic acid at the 340B discounted price. The facility purchases the drug at a steep discount and may pass some or all of that savings to the patient. The Health Resources and Services Administration oversees the 340B program 7.

Medicare Extra Help. Low-income Medicare beneficiaries may qualify for the Extra Help (Low-Income Subsidy) program, which reduces Part D premiums, deductibles, and copayments. While zoledronic acid typically falls under Part B rather than Part D, dual-eligible patients benefit from reduced overall medication costs.

Clinical Considerations That Affect Cost Decisions

Choosing zoledronic acid over alternatives involves weighing both clinical evidence and financial factors. The once-yearly dosing schedule offers a distinct adherence advantage. A meta-analysis published in Osteoporosis International found that adherence to oral bisphosphonates drops below 50% by 12 months 8. Poor adherence directly reduces fracture prevention benefit and increases downstream costs from fractures that could have been prevented.

The HORIZON Recurrent Fracture Trial (HORIZON-RFT, N=2,127) showed that zoledronic acid given within 90 days of surgical repair of a hip fracture reduced subsequent clinical fractures by 35% and all-cause mortality by 28% 9. Dr. Dennis Black of UCSF, a lead investigator, noted: "The mortality reduction was unexpected and may relate to anti-inflammatory effects of the drug beyond bone" 9. That mortality benefit has not been replicated in a dedicated confirmatory trial, but it adds context to the value proposition.

Renal function monitoring adds a small recurring cost. Serum creatinine must be checked before each annual infusion, and zoledronic acid is contraindicated when creatinine clearance falls below 35 mL/min. A basic metabolic panel at a Wisconsin lab typically runs $20 to $50 without insurance. Patients with borderline renal function may need the test repeated closer to the infusion date.

Post-infusion acute phase reactions (fever, myalgia, arthralgia) occur in roughly 30% of patients after the first dose, as reported in HORIZON-PFT 2. These symptoms typically resolve within 72 hours with acetaminophen or ibuprofen. The reaction rate drops to under 7% with subsequent annual doses. While not a direct financial cost, missed work days should factor into the overall cost calculation for employed patients.

How Wisconsin Compares to Neighboring States

Wisconsin's zoledronic acid pricing and coverage profile sits within the range of its Midwest neighbors. Average cash-pay pricing across retail pharmacies tracks close to the national mean. Medicaid coverage with prior authorization matches the approach used by Minnesota, Iowa, and Illinois.

One area where Wisconsin differs is 503A compounding access. Not all neighboring states have the same density of compounding pharmacies offering injectable bisphosphonates. Wisconsin's relatively permissive compounding regulations, combined with several PCAB-accredited pharmacies in the Milwaukee and Madison metro areas, give patients more options than some surrounding states.

The Inflation Reduction Act's Medicare drug pricing provisions, which took effect in stages starting in 2025, primarily affect Part D drugs rather than Part B physician-administered drugs like zoledronic acid 10. The $2,000 annual Part D out-of-pocket cap does not apply to Part B infusions. Wisconsin Medicare beneficiaries should understand this distinction when planning for osteoporosis treatment costs.

Annual zoledronic acid 5 mg IV remains one of the most cost-effective interventions per quality-adjusted life year (QALY) gained among osteoporosis therapies, with modeling studies estimating costs between $20,000 and $40,000 per QALY, well below the commonly cited $50,000 to $100,000 willingness-to-pay threshold 11.